Oncorus, Inc.

Cambridge, MA · Founded 2015 · CIK 0001671818 · Biotech · Defunct

Engineered oncolytic herpes simplex virus armed with immunostimulatory transgenes for intratumoral GBM treatment

oncorus.com →
Grants
$300K
1 award
Sector median: 1
Raised
$47M
2 Form D · Aug 2019
86 months since last filing
Contracts
—
No federal contracts on record
Patents
40
5 granted · 35 pending
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Private capital raisedForm D · SEC$4,612,500
Private capital raisedForm D · SEC$42,123,626
Federal grantDepartment of Health and Human Services · Phase I · Design of a micro-RNA attenuated armed oHSV for the treatment of glioblastoma$299,976
Federal grant · SBIR/STTRForm D · SEC

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
1199AIMMAX THERAPEUTICS INC—$200K
1200DMC BIOTECHNOLOGIES, INC.—$47M
1201Obatala Sciences, Inc.—$200K
1202Oncorus, Inc.—$47M
1203Qlaris Bio, Inc.—$42M
1204PLAKOUS THERAPEUTICS, INC.—$185K
1205ADIAL PHARMACEUTICALS, INC.—$38M

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Founders & Team

From Form D filings · 14 related persons
  • Theodore AshburnDirector · Executive Officer
  • Thomas ChalbergExecutive Officer
  • Luke EvninDirector
  • Mary Kay FentonDirector
  • Mitchell FinerDirector · Executive Officer
  • Robert KirkmanDirector
  • Alon LazarusDirector
  • John McCabeExecutive Officer
  • Briggs MorrisonDirector
  • Cyrus MozayeniExecutive Officer
  • Spencer NamDirector
  • Christophe QuevaExecutive Officer
  • Marc RechtExecutive Officer
  • Cameron WheelerDirector

Patents

USPTO · 5 granted of 40

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.